A randomized phase II trial reports the clinical efficacy of poly(ADP-ribose) polymerase (PARP) inhibitor olaparib combined with abiraterone in metastatic castration-resistant prostate cancer. At a cut-off date in September 2017, median radiographic progression-free survival was significantly longer in the abiraterone plus olaparib group than in the abiraterone plus placebo group (13.8 versus 8.2 months; HR 0.65, 95% CI 0.44–0.97, P = 0.034). Regarding safety, patients receiving the combination therapy had more grade 3 or worse and serious adverse events than those in the placebo arm.
References
Original article
Clarke, N. et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(18)30365-6 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bradley, C.A. Efficacy of a PARP inhibitor combination. Nat Rev Urol 15, 526 (2018). https://doi.org/10.1038/s41585-018-0048-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-018-0048-3
